Olfactory and gustatory function impairment in <scp>COVID</scp>‐19 patients: Italian objective multicenter‐study

Vaira, Luigi Angelo; Hopkins, Claire; Salzano, Giovanni; Petrocelli, Marzia; Melis, Andrea; Cucurullo, Marco; Ferrari, M; Gagliardini, Laura; Pipolo, Carlotta; Deiana, Giovanna; Fiore, Vito; Vito, Andrea De; Turra, Nicola; Canu, Sara; Maglio, Angelantonio; Serra, Antonello; Bussu, Francesco; Madeddu, Giordano; Babudieri, Sergio; Fois, Alessandro Giuseppe; Pirina, Pietro; Salzano, Francesco Antonio; Riu, Pierluigi De; Biglioli, Federico; Riu, Giacomo De

doi:10.1002/hed.26269

Cited by 246 publications

(343 citation statements)

References 27 publications

Supporting

Mentioning

299

Contrasting

Unclassified

Order By: Relevance

“…In this study chemosensitive dysfunction appeared in high percentage of the COVID-19 positive patients, 89.23% of patients had smell dysfunction and 83.08 had taste dysfunction. 2,6 Sudden Isolated chemosensitive dysfunction appeared in 18.46% and 15.38% for anosmia and taste loss respectively. Interestingly, that percentages were reported in patients who were tested because of only contact with COVID-19 relative; two of them reported the loss of smell as the rst symptom, while other 10 patients reported no rst complaint except contact with COVID -19 positive patient, and when it comes for the symptoms questionnaire, they had reported only chemosensitive dysfunction.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Incidence and Recovery of Chemosensitive Dysfunction in Covid-19 Positive Patients

Al-Zaidi

Badr²

2020

Preprint

View full text Add to dashboard Cite

Abstract Background: the objective of this study is to find the incidence of chemosensitive dysfunction in COVID-19 positive patients and its recovery.We collected the data from Sixty-five patients, all Covid-19 positive, quarantined in hospital between 5.4.2020 and 17.5.2020, by a questionnaire distributed the quarantine ward.Results: Smell dysfunction appeared in (89.23%) with or without other symptoms of COVID-19. (39.66%) had the sense of smell recovered. Taste dysfunction was found in (83.08%) patients with other COVID-19 symptoms. only (29.63%) of them recovered. The recovery took 1-3 weeks, most cases within 1 week or less. As the only symptom before COVID-19 confirmation, (18.46%) and (15.38%) had smell dysfunction and taste dysfunction respectively. Most of the chemosensitive dysfunction affected the 4th decade of age.Conclusion: Chemosensitive dysfunction is associated with COVID-19, and may be the only presenting symptom of the disease. This makes the ENT doctors in the first line of contact with corona virus. Further objective studies are required to cover chemosensitive dysfunctions, as the recognition of this dysfunction may help the diagnosis of COVID-19, and prevent the spread of this disease.

show abstract

Section: Discussionmentioning

confidence: 99%

“…However, other studies reported this gender percentage. [5][6][7][8] Most cases were mild, followed by moderate, then total anosmia and or taste loss. There must recognition of the patient felling to have chemosensitive disorders and the real presence of such dysfunction, i.e.…”

Section: Discussionmentioning

confidence: 99%

Incidence and Recovery of Chemosensitive Dysfunction in Covid-19 Positive Patients

Al-Zaidi

Badr²

2020

Preprint

View full text Add to dashboard Cite

show abstract

“…2 The prevalence of OD may vary regarding the clinical setting, with rates of total loss of smell as high as 70% in patients with mild COVID-19 form. 2,4,5 The prevalence of OD in moderate-to-critical COVID-19 forms was poorly investigated. Moreover, there is, to date, a paucity of studies prospectively studying the recovery rates of smell sense in COVID-19 patients.…”

Section: Introductionmentioning

confidence: 99%

Prevalence and Recovery of Olfactory Dysfunction in 1,363 patients with coronavirus disease 2019: A Multicenter Longitudinal Study.

Lechien

Chiesa‐Estomba

Beckers³

et al. 2020

Preprint

View full text Add to dashboard Cite

Abstract Olfactory dysfunction (OD) is a key symptom of coronavirus disease 2019 (COVID-19). Currently, a few data are available about the recovery of OD after the infection resolution. In this study, we investigated both prevalence and recovery rate of OD with subjective and objective clinical tools in 2,581 patients. First, our data showed that the prevalence of OD was significantly higher in mild form (85.9%) compared with moderate-to-critical forms (4.5-9.7%; p=0.001). Second, focusing on patients with OD who completed the 2-month follow-up period (N=1,363), we observed that 328 patients (24.1%) did not subjectively recover olfaction 60 days after the onset of the dysfunction. The mean duration of self-reported OD was 21.6±17.9 days. Third, the objective olfactory evaluations performed on a subset of patients (N=233) reported hyposmia or anosmia in 54.7% and 36.6% of mild and moderate-to-critical forms, respectively (p=0.001). At the end of follow-up, 15.3% of anosmic/hyposmic patients did not objectively recover olfaction. The higher baseline severity of objective olfactory evaluations was strongly predictive of persistent OD (p<0.001). OD disappeared in 75% to 85% of patients regarding self-reported or objective olfactory evaluations.

show abstract

“…Emerging studies based on objective evaluation of patients in fact suggest that there is no significant correlation between the prevalence of chemosensitive disorders and COVID-19 severity, supporting this proposal. [3][4][5] Furthermore, in our recent analysis of a series of 345 cases, patients with a duration of chemosensi- tive symptoms of >7 days had a 2.33-fold greater risk of developing severe symptoms. 5 We also demonstrated how anamnestic data collection underestimates the frequency of chemosensitive disorders detected in psychophysical tests, particularly in patients with a more serious presentation.…”

mentioning

confidence: 95%

“…[3][4][5] Furthermore, in our recent analysis of a series of 345 cases, patients with a duration of chemosensi- tive symptoms of >7 days had a 2.33-fold greater risk of developing severe symptoms. 5 We also demonstrated how anamnestic data collection underestimates the frequency of chemosensitive disorders detected in psychophysical tests, particularly in patients with a more serious presentation. It seems likely that these patients have the same prevalence of chemosensitive dysfunction as patients with mild and moderate forms but neglect these symptoms while suffering with and receiving supportive treatment for severe respiratory disease.…”

mentioning

confidence: 95%

Self‐reported olfactory loss in COVID‐19: is it really a favorable prognostic factor?

Hopkins

Vaira

Riu

2020

Int Forum Allergy Rhinol

Self Cite

View full text Add to dashboard Cite

Olfactory and gustatory function impairment in COVID‐19 patients: Italian objective multicenter‐study

Cited by 246 publications

References 27 publications

Incidence and Recovery of Chemosensitive Dysfunction in Covid-19 Positive Patients

Incidence and Recovery of Chemosensitive Dysfunction in Covid-19 Positive Patients

Prevalence and Recovery of Olfactory Dysfunction in 1,363 patients with coronavirus disease 2019: A Multicenter Longitudinal Study.

Self‐reported olfactory loss in COVID‐19: is it really a favorable prognostic factor?

Contact Info

Product

Resources

About